Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Argatroban with dual antiplatelet therapy for watershed cerebral infarction
ChiCTR2100045812Phase 4Recruiting
- Sponsor
- Affiliated Hospital of Jiujiang University
- Start
- May 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of argatroban, aspirin and clopidogrel in brain infarction and ischemic stroke (3 arms), sponsored by Affiliated Hospital of Jiujiang University. Primary endpoint: Incidence of progressive cerebral infarction within 1 week after randomization. Started May 2021; status: recruiting.
02
Drugs
argatrobanaspirinclopidogrel
03
Conditions
brain infarctionischemic stroke
Beyond the preview
Go deeper on ChiCTR2100045812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045812.